



## **Sunday December 15, 2024**

16:00 *Registration*

17:00 Welcome - (Jean-Louis Vincent)

17:10 Current thinking on the pathogenesis of sepsis - (Joost Wiersinga)

17:20 Reframing sepsis for clinical practice: beyond consensus conferences - (John C Marshall)

17:40 Current criteria in children - (Luregn Schlapbach)

18:00 Organ shutdown: adaptive versus maladaptive - (Mervyn Singer)

18:20 Lung microbiome changes are important matters - (Massimo Antonelli)

18:40 Have outcomes from sepsis improved? - (Hallie Prescott)

19:00 Discussion

### **Round table**

19:30 Antimicrobial stewardship - (Jan De Waele, Fabio S Taccone, Evelina Tacconelli)

20:00 End of the day

**Monday, December 16, 2024**

**Novel diagnostics**

08:30 Gene expression to characterize the host response - (Luregn Schlapbach)

08:50 New technology to detect pathogens... - (Jan De Waele)

09:10 ...and to orient antibiotic therapy - (Mervyn Singer)

09:30 Clinical impact - (Evelina Tacconelli)

09:50 Discussion

10:00 Break

**Initial antibiotic therapy**

10:30 Optimal selection - (Hallie Prescott)

10:50 Let us prefer microbiome-friendly antibiotics - (Joost Wiersinga)

11:10 We need a personalized approach - (Evelina Tacconelli)

11:30 Initial dosing: same for all? (Jan De Waele)

11:50 Discussion

**Plenary lecture**

12:00 Adjuvant treatments for sepsis: insights from rheumatology - (John C Marshall)

**Round table**

12:20 Sepsis bundles - (Hallie Prescott, Mervyn Singer, Fabio S Taccone, Massimo Antonelli)

12:40 Lunch

**Early therapeutic strategies**

13:30 Does faster treatment of sepsis derail stewardship? - (Hallie Prescott)

13:45 My antibiotic guidelines - (Mervyn Singer)

14:00 When to intubate the trachea - (Massimo Antonelli)

14:15 Discussion

14:30 Early hemodynamic management - (Jean-Louis Vincent)

14:45 Corticosteroids from the start? - (Joost Wiersinga)

15:00 Discussion

15:10 Break

### **Sepsis bundles**

15:30 US policy efforts: all good? - (Hallie Prescott)

15:45 The dangers of sepsis bundles - (Mervyn Singer)

16:00 Discussion

### **Plenary lecture**

16:10 What's new in pneumonia management? - (Joost Wiersinga)

### **Round Table**

16:30 How I see the future - (Mervyn Singer, Evelina Tacconelli, Joost Wiersinga, John C Marshall)

### **Clinical Case**

17:00 An infectious disease specialist - (Evelina Tacconelli)

17:20 End of the day

**Tuesday, December 17, 2024**

### **Antimicrobial management**

08:30 My top papers of the last year - (Joost Wiersinga)

08:45 Antibiotic strategy for resistant Gram-negative bacteria - (Evelina Tacconelli)

09:00 Let us consider the side effects - (Fabio S Taccone)

09:15 Antibiotic de-escalation: always yes, sometimes maybe? - (Jan De Waele)

09:30 Interest of D-glucan in fungal infections - (Massimo Antonelli)

09:45 Sepsis in LMICs: the burden of tropical infections and antimicrobial resistance  
- (Joost Wiersinga)

10:00 Probiotics: current status - (Joost Wiersinga)

10:15 Discussion

10:30 Break

### **Pro & con debate**

10:50 Biomarkers to guide antibiotic therapy

- Pro: Antibiotic duration should be individualized - (Jean-Louis Vincent)
- Con: Biomarkers are not very useful if you do things right - (Jan De Waele)

### **Source control**

11:20 A practical strategy - (Jan De Waele)

11:35 Does the timing really matter? - (Massimo Antonelli)

11:50 Discussion

### **Round table**

12:00 How to improve quality - (Luregn Schlapbach, Jan De Waele, Evelina Tacconelli, Hallie Prescott)

12:20 Lunch

### **Sepsis therapies**

- 13:00 Anti-TNF strategies could still make sense - (John C Marshall)
- 13:15 Towards novel immunotherapies - (Joost Wiersinga)
- 13:30 Targeting bioenergetics and metabolism - (Mervyn Singer)
- 13:45 Discussion

### **Organ function and support**

- 14:00 Cardiomyopathy - (Mervyn Singer)
- 14:15 Encephalopathy - (Fabio S Taccone)
- 14:30 Respiratory failure - (Massimo Antonelli)
- 14:45 Renal protection - (Jean-Louis Vincent)
- 15:00 We will have a SOFA-2 score - (Mervyn Singer)
- 15:15 Discussion
- 15:30 Break

### **Preventing the catastrophe**

- 15:45 We need better public awareness - (Luregn Schlapbach)
- 16:00 Managing sepsis outside the hospital - (Hallie Prescott)
- 16:15 Any role for prophylactic agents? - (John C Marshall)
- 16:30 SDD: current status - (Jan De Waele)
- 16:45 Discussion
  
- 17:00 End of the day

**Wednesday, December 18, 2024**

### **Long-term outcomes**

08:30 Post sepsis syndromes - (Evelina Tacconelli)

08:45 In adults - (Hallie Prescott)

09:00 In children - (Luregn Schlapbach)

09:15 Discussion

### **Quality improvement**

09:30 A pediatrician's view - (Luregn Schlapbach)

09:45 Implementation of stewardship interventions - (Evelina Tacconelli)

10:00 We need collective action - (Hallie Prescott)

10:15 Discussion

### **Concepts for the future**

10:30 Precision medicine for all - (Luregn Schlapbach)

10:45 What the future guidelines will look like - (Joost Wiersinga)

11:00 Sepsis definitions (or criteria) will evolve - (Mervyn Singer)

11:15 We may no longer need the word 'sepsis' - (John C Marshall)

11:30 Discussion

### **Clinical trials**

11:45 Rethinking sepsis trials: basket and platform trials - (John C Marshall)

12:00 We should design joint adult–pediatric trials - (Luregn Schlapbach)

### **Clinical cases**

12:15 Clinical approach to a patient with suspected sepsis - (Jan De Waele)

12:30 Clinical approach to a child with possible sepsis - (Luregn Schlapbach)

### **General discussion**

12:45 Remaining questions - (entire faculty)

13:00 End of the meeting